Pedro Velasquez, MD
Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1003874801
Payments from drug & device makers
Across 249 payments — averaging $9761.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$412K
- Eli Lilly$354K
- AbbVie$335K
- Astrazeneca UK Limited$302K
- Novo Nordisk$280K
- Bayer$270K
- plus $478K from 16 others
Across 5 payments — averaging $2426.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$11K
- Eli Lilly Export S.A. Puerto Rico Branch$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $412,408 |
| Eli Lilly | 8 | $353,850 |
| AbbVie | 10 | $334,777 |
| Astrazeneca UK Limited | 15 | $301,817 |
| Novo Nordisk | 29 | $280,232 |
| Bayer | 60 | $269,912 |
| Boehringer Ingelheim | 11 | $207,363 |
| Janssen Research & Development, LLC | 23 | $126,453 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 23 | $79,052 |
| Novo Nordisk AS | 2 | $49,180 |
| Boehringer Ingelheim France S.a.s. | 20 | $7,329 |
| Johnson & Johnson | 11 | $5,433 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $2,566 |
| Corcept Therapeutics | 5 | $91 |
| Ultragenyx Pharmaceutical Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Rhythm Pharmaceuticals, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $18 |
| Insulet Corporation | 1 | $14 |
| Merck | 1 | $14 |
| Abbott | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$2,430,661 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Memphis
- Lisa UsdanMemphis$14.3M
- Alan CohenMemphis$1.5M
- Aidar GosmanovMemphis$833K
- Shimon HararyMemphis$735K
- Samuel Dagogo-JackMemphis$476K
- Ebenezer NyenweMemphis$438K
- Richard ChildressMemphis$212K
- Deirdre JamesMemphis$92K
- Malini GuptaMemphis$91K
- Benjamin BrannickMemphis$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.